Hangzhou Sumgen Biotech Co., Ltd. (hereinafter referred to as Sumgen Biotech or the "Company") is an innovation-driven biopharmaceutical company dedicated to development and commercialization of innovative antibodies for cancer and other life-threatening malignancies. Dr. Lv obtained his bachelor's degree in Zhejiang University and completed his PhD degree in AMMS. His supervisor, academician Beifen Shen, is a national-renowned immunologist, who laid the foundation of immunology research in China. After graduation, Lv stayed on as assistant of Academician Shen to conduct her research. In 2014, Dr. Lv developed the anti-Ebola antibody MIL77, which successfully cured British female soldiers and received high attention and recognition from the government.

Sumgen holds the belief that technology innovation leads to product innovation. Over the past 5 years, we are led by a professional management team and scientific advisory board including key opinion leaders from research institute, experts at home and abroad highly experienced in biopharmaceutical industry. Early-stage R&D centers located in Beijing with headquarters in Hangzhou. We have successfully built an integrated process covering antibody discovery to scale-up manufacturing and clinical development, and established robust pipeline focusing on oncology with more than 70 patents applications. SG001 entered Phase II stage in 2021, and other ongoing programs steadily move forward such as SG301, SG404, SG12473 and SG2501. Sumgen secured multiple funding rounds from Hankang Capital, China National Biotech Group (CNBG), Addor Capital, Sinowisdom, Cowin Capital, Junchuan Capital, Zheshang Venture Capital and other institutions; established partnership with CSPC for SG001 project. In Mar. 2020, joint venture CNBG Sumgen Biopharmaceutical (Hangzhou) Co., Ltd. established to further accelerate the industrialization of Sumgen pipeline assets.

Supported by Governments and institutions, Sumgen Biotech has initiated the GMP Manufacturing Site Construction Project. With a 2-year plan to build a large-scale production base for antibody drugs that complies with international regulations, to rapidly promote the industrialization of several innovative antibodies, and to strive to become an internationally leading, sustainably innovative biopharmaceutical company that provides high-quality Chinese antibodies to patients worldwide.

Copyright Rm. 301, F3, Building C, Block 2, No. 688, Bin'an Road, Changhe Zhejiang ICP Filing No. 18039044